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ABSTRACT
Aim: To identify the severity of Frey’s syndrome and its response to botulinum toxin type A. Methods: Minor test was 
performed in all cases to assess the extent of the affected area, using the contralateral side as control. Severity was as-
sessed according to the proposal of Luna-Ortiz et al. Response was evaluated after 3 and 6 months, and was compared 
with the basal data. Results: Frey’s syndrome was documented in 38 patients, but only 23 cases accepted the botulinum 
toxin type A treatment. Severity was moderate in 8 (35%) and severe in 15 (65%) cases. Mean applied dose was 1.41 
MU/cm2 in 21 patients (91%), whereas one patient was treated with 10 MU for a 0.8 cm2 affected area (12.5 MU/cm2) and 
another patient with 10 MU for a 0.5 cm2 affected area (20 MU/cm2) due to severity of their symptomatology. Average 
affected area at the beginning was 14.2 cm2, while after 3 and 6 months of treatment it was 4.1 cm2 and 4.4 cm2 respec-
tively (p<0.001). The two patients that received higher doses of botulinum toxin A had complete response. Complete 
response was observed in 13 patients (56.5%) at 3 months, but in only nine (39%) this lack of symptomatology persisted 
at 6 months. In three cases (13%) no response was obtained at 3 months, and the application of an additional dose of 
botulinum toxin type A produced no response in two of them after 6 months.  Comparison of the severity score of the 
average basal value vs. that obtained at 3 and 6 months revealed a significant difference (p< 0.05); however, no statisti-
cally significant difference was found when comparing outcome at 3 vs. 6 months. There were no statistically significant 
differences using the independent samples test when comparing outcome after treatment in relation to gender, type of 
surgery, or use of postoperative radiation therapy (p>0.05). In conclusion, botulinum toxin A remains as the treatment 
of choice for Frey’s syndrome.   
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INTRODUCTION
Gustatory sweating is caused by the disruption of  the 
auriculotemporal nerve branches, followed by an aberrant 
regeneration resulting in a parasympathetic reinervation 
with sympathetic receptors. This alteration is known as 
Frey’s syndrome (1) based on its first description made by 
the Polish neurologist Lucja Frey, with an incidence of 5 to 
100% in patients subjected to parotidectomy and a mean 
incidence estimated in 66% (2,3). In a previous study we 
found an incidence of 36% in a Mexican population (4). 
Several treatments have been proposed to avoid this com-
plication, including interpositional barriers by means of 
dermis grafts (5,6), acellular human dermal matrix grafts 
(7), synthetic implants (8), interposition of fascia or muscle 
flaps (9-15), section and ligature of the auriculotemporal 
nerve (16), as well as other methods aimed at reducing its 
intensity by means of topical application of anticholinergic 
agents (17,18) and, recently, with the injection of botulinum 
toxin type A (19,20).  
The present study was aimed at identifying the severity of 
Frey’s syndrome and its response to botulinum toxin type A 
in patients treated at a cancer center in Mexico City.
MATERIAL AND METHODS
This observational study was carried out in patients that 
had a minimal time of 6 months since they were submitted 
to partial or total parotidectomy and were under periodic 
control at the Head and Neck Department at the Instituto 
Nacional de Cancerologia in Mexico City, regardless of age 
or age, with or without antecedents of medical or surgical 
treatment to prevent or to reduce the incidence and/or seve-
rity of the symptomatology caused by Frey’s syndrome. 
In all cases the starch-iodine Minor (21) test was performed 
in order to assess the existence and extension of the affec-
ted area (Figure 1), using the contralateral side as control 
in all cases. The affected area (Figure 2) was drawn on a 
transparent acetate sheet and extension was expressed in 
square centimeters (cm2) (Figure 3). The degree of severity 
was assessed in each patient according to the proposal of 
Luna-Ortiz et al.(4), which includes four items as described 
in Table I. All patients who accepted treatment signed an 
informed consent, and each of them received intradermally 
botulinum toxin type A (Botox, Allergan 100 mouse units 
(MU)/4 ml 0.9% saline solution, Mexico City, Mexico) 
applied homogeneously on the previously marked affected 
area. Response to treatment was evaluated through the 
Minor test and the degree of severity at 3 and 6 months 
after application of the botulinum toxin type A, and the 
corresponding figures were compared with the basal ones 
in each case. Results were assessed by means of Student’s t 
and Chi square tests, and, in some instances, by means of 
the independent samples test.
RESULTS
There were a total of one hundred patients (36 men and 64 
women) that were evaluated after partial or total parotidec-
tomy; of these, ninety-seven had been surgically intervened 
due to parotid tumors and 3 because of irreversible chronic 
inflammatory processes. Frey’s syndrome was documented 
in 38 cases, with an average age of 46.7 years (range, 18 to 
70 years). There were 25 women (66%) and 13 men (34%). 
Of these, sixteen patients (42%) had been subjected to total 
parotidectomy and 22 (58%) to partial parotidectomy.  Seven 
cases (18.4%) received adjuvant therapy as part of their on-
cological treatment. The average affected area was 10.32 cm2 
Fig. 1. Positive Minor test on two isolated areas in the pre-
auricular region.
Fig. 2. Affected area drawn directly on the skin after removal 
of the starch powder.
Fig. 3. Affected area of the same patient of Figures 1 and 2 expressed in 
square centimeters recorded on an acetate.. Total affected area: 7.98 cm2.
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            Yes 





 15  (65%) 
   8 (35%) 
Extent of affected area 
            0.1-2.0 cm 
            2.1-4.0 cm 




7 (18.4 %) 
6 (15.8 %) 




Excessive Focal Sweating 3 18 (47.3 %) 12 (52%) 
Unpleasant Smell Sweating 3 1 (2.6 %) 1 (4.3%) 
Mild Frey´s Syndrome 1-3 points 12 (31.5%) 8 (35%) 
Severe Frey´s Syndrome >4 points 26 (68.5%) 15 (65%) 
(range: 1 to 30 cm2). Severity in this group of patients was 
moderate in 12 (31.5%) and severe in 26 (68.5%), as shown 
in Table I. Contralateral side was negative in all patients.
Only 23 (8 men and 15 women) of the 38 patients accepted the 
botulinum toxin type A treatment. Severity in these cases was 
moderate in 8 (35%) and severe in 15 (65%).  Mean applied 
dose was 1.41 MU/cm2 of the affected skin area in 21 patients 
(91%), whereas one female patient was treated with 10 MU 
for a 0.8 cm2 affected area (12.5 MU/cm2) and one male 
patient was treated with 10 MU for a 0.5 cm2  affected area 
(20 MU/cm2) due to the severity of their symptomatology. 
The average affected area at the beginning of the study was 
of 14.2 cm2, which ranged from 0.5 to 29.8cm2 (15.1 for men 
and 13.81 in women). The mean affected area after 3 months 
of treatment was 4.1 cm2 (5.1 cm2 for men and  3.5 cm2 for 
women); however  3 patients (13%) required a second appli-
cation of the botulinum toxin due to lack of response to the 
initial treatment. The average affected area at 6 months was 
4.4 cm2 (7.48 cm2 for men and 2.75 cm2 for women). The 
two patients that received higher doses of botulinum toxin A 
than the rest of the group had complete response.
Table II depicts the affected area for each patient at the 
beginning and at 3 and 6 months of treatment, revealing 
a response of 79.3% at 3 months and 73.8% at 6 months. 
Comparisons of  the extent of the affected area at baseline 
with that found at 3 and 6 months revealed a statistically 
significant difference (p<0.001) between the initial figure 
and those recorded at 3 and 6 months; however, comparison 
between 3 and 6 months revealed no significant difference 
(p=0.726).  
In three cases (13%) no response was obtained at 3 months, 
and the application of an additional dose of botulinum toxin 
type A produced no response in two of them after 6 months. 
Comparison of the severity score of the average basal value 
vs. that obtained at 3 and 6 months revealed a significant 
difference (p< 0.05); however, no statistically significant 
difference was found when comparing outcome at 3 vs. 6 
months. There were no statistically significant differences 
using the independent samples test when comparing outco-
me after treatment in relation to gender, type of surgery, or 
use of postoperative radiation therapy (p>0.05).
 
Table I. Evaluation of severity among Frey´s syndrome patients *
* According to Luna-Ortiz K. et al4. 
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1 15 0.3 (98) 2.8 (81.3) 7 0 2 
2 22.2 0.1 (99) 0 (100) 7 0 0 
3 0.8 0 (100) 0 (100) 1 0 0 
4 0.5 0 (100) 0 (100) 5 0 0 
5 25 1 (96) 2.3 (90.8) 7 1 2 
6 3.9 0 (100) 2.6 (33.3) 3 0 2 
7 3.9 0.3 (92) 0 (100) 2 1 0 
8 27 17 (37) 4.4 (83.7) 7 7 3 
9 20 2.2 (89) 3.5 (82.5) 3 2 2 
10 29.8 8.2 (72.4) 9.6 (67.7) 7 7 7 
11 17 5.2 (69.4) 7.3 (57) 10 7 7 
12 5.2 0 (100) 0 (100) 3 0 0 
13 9.3 0 (100) 6.8 (26.8) 7 0 7 
14* 14 14.4 (0) 9.5 (32.1) 3 3 3 
15* 8.2 9.9 (0) 8.9 (0) 4 4 4 
16 10.7 0 (100) 2.9 (72.9) 4 0 3 
17 12.1 0 (100) 0 (100) 7 0 0 
18* 25.3 28 (0) 34.5 (0) 7 7 7 
19 17 0 (100) 0 (100) 6 6 6 
20 29.7 8.3 (72) 3.09 (89.5) 7 7 2 
21 8 0 (100) 0 (100) 3 0 0 
22 7 0 (100) 0 (100) 2 0 0 
23 16.4 0 (100) 3 (81.7) 7 0 3 
Mean 14.2 4.1 (79.2) 4.4 (73.8) 7 0 3 
Table 2. Response to treatment with intracutaneous botulinum toxin type A
* unresponsive patients
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DISCUSSION
The pathogenesis of Frey’s syndrome is not fully understo-
od. The most frequent hypothesis relates this syndrome to 
a misdirected regeneration of postganglionic nerve fibers 
of the auriculotemporal and greater auricular nerve. After 
nerve injury, these nerve fibers connect to injured postagan-
glionic sympathetic nerve fibers innervating sweat glands 
and small skin vessels, producing sweating under gusta-
tory stimuli (“gustatory sweating”). It has been suggested 
that the probability one individual has for developing this 
syndrome could be related to the amount of tissue that is 
removed during parotidectomy (22); however, this seems 
quite unlikely since although this syndrome has been re-
ported mainly associated to the parotid, it has also been 
reported in association with trigeminal nerve infection by 
herpes virus, post-parotiditis, secondary to condylar frac-
tures, after traumatisms with forceps, and after surgery for 
meningiomas located in the pontocerebellar angle, in which 
parotid tissue is not removed (23). The present study revea-
led no difference regarding its presence in patients that were 
subjected to superficial or total parotidectomy. 
According to the diverse series, the incidence of post-pa-
rotidectomy Frey’s syndrome has been reported in a mean 
of 66%. However, this figure varies widely according to 
the criteria employed to diagnose this condition. The most 
frequently used diagnostic criterion is the objective one, 
by means of the starch-iodine Minor test (21). We found a 
38% frequency of post-parotidectomy Frey syndrome when 
diagnosed with the Minor test; however, this incidence was 
lower when diagnosis was based solely on clinical criteria 
(26%). This phenomenon has been previously reported (4), 
suggesting that there is an asymptomatic presentation of this 
disorder, in which clinical manifestations are so mild that 
the patient is unable to perceive them. Another possibility 
that could explain this low incidence is that the physician 
does not detect it, either because he/she is unaware of the 
disorder or considers it so uncommon that pays no atten-
tion to it, or perhaps, during examination, questions only 
address the presence of symptoms. This situation, as has 
been proven in questionnaires related to epidemiological 
studies for validation, leads to low detection sensitivity 
and specificity (24). Therefore, we recommend that every 
patient treated by means of partial or total parotidectomy 
be periodically subjected to a complete evaluation, including 
the Minor test.  
The average affected area during basal measurement in this 
study was 14.2 cm2 (range,  0.5 to 29.8cm2), which seems 
lower than those reported in other series, where it ranges 
from 25 to 175 cm2 (25), 16 to 81 cm2 (26), and  36 to 80 
cm2 (22); however, no particular explanation seems to exist 
for this difference. 
The use of botulinum toxin type A for the treatment of 
Frey´s syndrome was introduced by Drobik and Laskawi 
(19); the dose used in that study was of 0.5 MU; howe-
ver, the optimal dose has not been establish yet, as it has 
been applied in diverse studies from 0.5 MU to 5 MU 
(19,23,27,28). Likewise, no relation dose-area has been 
established yet, since schemes of  0.5 MU/4 cm2 (19), 2.5 
MU/cm2, (26,29), 1 MU/cm2, , and 1 to 2 MU/2.25 cm2 (25) 
have been used. One explanation of this diversity may be that 
severity of Frey syndrome has not been clearly defined in all 
series. Recently, Luna-Ortiz et al published a series of cases 
and proposed an objective method for evaluating severity, 
which has been used in the present study (4). In our series 
we used a mean dose of 1.41 MU/cm2 of the affected skin 
area in 21 (91%) patients, although one female patient was 
treated with 10 MU for an affected area of 0.8 cm2 (12.5 
MU/cm2) and one male patient with 10 MU for an affected 
area of  0.5 cm2 (20 MU/cm2) due to the severity of their 
symptomatology. The observed overall response was of 
79.2% at 3 months and of 73.8% at 6 months. Three patients 
did not respond initially and only one of them responded 
after the second application. Thirteen (56.5%) patients had 
a complete response at 3 months, but only 9 of them (39%) 
persisted with complete response at 6 months of follow up, 
which reveals a clear tendency to recurrence, as has been 
shown in another study (25). However, severity downgrading 
of the symptomatology is clearly diminished when compa-
ring the basal measurement vs. that obtained at 3 months 
in 14 (60.8%) patients and in 15 (65%) at 6 months. 
Several treatment have been used to prevent Frey’s syndro-
me, such as placement of interpositional barriers, going 
from dermal grafts (5,6), acellular human dermal matrix 
grafts (7), synthetic implants (8), interposition of fascia or 
muscle flaps (9-15), or even section or ligature of the auri-
culotemporal nerve (16); however, none of these methods 
prevents this complication in 100% of cases, which means 
that another mechanism might be involved besides the 
anomalous neural regeneration. Another disadvantage of 
the preventive measures is the over-treating of 62% of the 
patients subjected to parotidectomy that do not develop this 
syndrome (4); besides,  a large number of salivary fistulas 
(57%) has been observed after some of these therapeutic 
modalities, especially when using synthetic materials (8). 
CONCLUSION
Incidence of  Frey’s syndrome in our population is less 
than 40%, with important differences regarding the extent 
of  the affected area as compared with that reported for 
Anglo-Saxon patients, who present higher values. The 1.41 
MU/cm2 dose used in this study demonstrated a 79% res-
ponse; however, two patients did not respond at all. Thus 
far, botulinum toxin A remains as the treatment of choice 
for the management of Frey’s syndrome. 
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